Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combe co-founder dies

This article was originally published in The Tan Sheet

Executive Summary

Mary Elizabeth Deming Combe, who co-founded Combe Inc. with her husband Ivan Combe, died Sept. 20 in Greenwich, Conn., at age 94. The privately held White Plains, N.Y.-based firm makes skin care brand Lanacane, Cepacol lozenges and Vagisil feminine itch care products. Ivan Combe, who died in January 2000, served 35 years on the board of the Consumer Healthcare Products Association through several of the trade group's incarnations (1"The Tan Sheet" Jan. 17, 2000). The couple's son Chris Combe is chairman and CEO of the company, and Chris Combe's daughter Keech Combe Shetty is global director of Combe Inc.'s feminine care category

You may also be interested in...

OTC, Toiletry Industries Leader Combe Dies At Age 88

CHPA 35-year board member Ivan Combe died Jan. 11 following a stroke. With his death, the OTC drug and toiletry industries have lost a leader who represented the dwindling number of privately owned companies still run by their founder.

Genus Triumphs Over FDA In Barium Sulfate Product Classification Suit

The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.

Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis

Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts